Brief: Revive Therapeutics Provides Update Of Psilocybin Pharmaceutical Programs
17/01/2022 13:47
Jan 17 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE OF PSILOCYBIN
PHARMACEUTICAL
PROGRAMS
* REVIVE THERAPEUTICS LTD - IRB APPROVAL TO INITIATE PHASE 2
STUDY
FOR METHAMPHETAMINE ABUSE DISORDERS
* REVIVE THERAPEUTICS LTD - ENTERED INTO A RESEARCH
COLLABORATION
AGREEMENT WITH PHARMATHER HOLDINGS LTD
* REVIVE THERAPEUTICS - EXPECTS TO COMPLETE A RESEARCH-GRADE
BATCH
OF PSILOCYBIN FOR RESEARCH IN Q2-2022 WITH AIM TO CONDUCT
CLINICAL STUDIES IN 2023
Source text for Eikon: ID:nGNX38VCpn
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application